Insider · CIK 0001731193

AHMED NADIM

Reports to the SEC for 4 companies · WATERTOWN, MA

sec.gov

Transactions

Companies

Filings

CIK

0001731193

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-18	IRONDisc Medicine, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+5,176 sh	—	—	5,176
2026-02-24	CGEMCullinan Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−13.5K sh	$14.47	−$196K	390,803
2026-02-20	CGEMCullinan Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−16.4K sh	$13.62	−$223K	404,318
2026-02-18	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+828K sh	—	—	828,000
2025-12-23	CGEMCullinan Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−9,922 sh	$10.01	−$99.3K	420,699
2025-07-14	IRONDisc Medicine, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2025-02-25	CGEMCullinan Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−12.5K sh	$8.53	−$107K	430,621
2025-02-19	CGEMCullinan Therapeutics, Inc.A Award	Director, President and CEO	AAward	+180K sh	—	—	443,150
2025-02-19	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+360K sh	—	—	360,000
2024-12-24	CGEMCullinan Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−8,400 sh	$11.87	−$99.7K	263,150
2024-02-22	CGEMCullinan Therapeutics, Inc.A Award	Director, President and CEO	AAward	+160K sh	—	—	271,550
2024-02-22	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+320K sh	—	—	320,000
2023-12-26	CGEMCullinan Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−4,272 sh	$9.24	−$39.5K	111,550
2023-06-28	CGEMCullinan Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−759 sh	$11.40	−$8,652.6	115,822
2023-05-23	CGEMCullinan Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−707 sh	$9.15	−$6,469.05	116,581
2023-04-25	CGEMCullinan Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−716 sh	$10.59	−$7,582.44	117,288
2023-03-23	CGEMCullinan Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−706 sh	$10.51	−$7,420.06	118,004
2023-02-22	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+211K sh	—	—	211,000
2023-02-22	CGEMCullinan Therapeutics, Inc.A Award	Director, President and CEO	AAward	+109K sh	—	—	118,710
2022-06-30	CGEMCullinan Therapeutics, Inc.A Award	Director, President and CEO	AAward	+1,620 sh	$10.90	+$17.7K	9,710
2022-06-06	CGEMCullinan Therapeutics, Inc.P Purchase	Director, President and CEO	PPurchase	+8,090 sh	$12.40	+$100K	8,090
2022-03-05	CGEMCullinan Therapeutics, Inc. · Performance Stock UnitA Award	Director, President and CEO	AAward	+215K sh	—	—	215,000
2021-10-18	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+2.71M sh	—	—	2,710,000
2020-12-31	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsM Exercise/Conversion	EVP and President, Hematology	MExercise/Conversion	−14.9K sh	—	—	0
2020-12-31	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP and President, Hematology	MExercise/Conversion	+14.9K sh	—	—	46,549
2020-12-31	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP and President, Hematology	FTax Payment	−7,660 sh	$62.03	−$475K	38,889
2020-12-02	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP and President, Hematology	MExercise/Conversion	+6,594 sh	—	—	34,983
2020-12-02	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsM Exercise/Conversion	EVP and President, Hematology	MExercise/Conversion	−6,594 sh	—	—	19,782
2020-12-02	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP and President, Hematology	FTax Payment	−3,380 sh	$62.18	−$210K	31,603
2020-10-30	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsM Exercise/Conversion	EVP and President, Hematology	MExercise/Conversion	−4,650 sh	—	—	0
2020-10-30	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP and President, Hematology	FTax Payment	−2,291 sh	$58.45	−$134K	28,389
2020-10-30	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP and President, Hematology	MExercise/Conversion	+4,650 sh	—	—	30,680
2020-05-01	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsM Exercise/Conversion	EVP and President, Hematology	MExercise/Conversion	+2,908 sh	—	—	0
2020-05-01	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP and President, Hematology	MExercise/Conversion	+2,908 sh	—	—	27,463
2020-05-01	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP and President, Hematology	FTax Payment	−1,433 sh	$60.26	−$86.4K	26,030
2020-03-10	BMYBRISTOL MYERS SQUIBB CO · Performance SharesA Award	EVP and President, Hematology	AAward	+32.1K sh	—	—	32,082
2020-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsA Award	EVP and President, Hematology	AAward	+21.4K sh	—	—	21,388
2020-03-01	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP and President, Hematology	FTax Payment	−8,473 sh	$59.06	−$500K	24,555
2020-03-01	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsM Exercise/Conversion	EVP and President, Hematology	MExercise/Conversion	+17.2K sh	—	—	34,410
2020-03-01	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP and President, Hematology	MExercise/Conversion	+17.2K sh	—	—	33,028
2020-02-04	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsM Exercise/Conversion	EVP and President, Hematology	MExercise/Conversion	+2,076 sh	—	—	4,152
2020-02-04	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP and President, Hematology	FTax Payment	−1,071 sh	$64.29	−$68.9K	15,824
2020-02-04	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP and President, Hematology	MExercise/Conversion	+2,076 sh	—	—	16,895
2019-12-02	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsA Award	EVP and President, Hematology	AAward	+26.4K sh	—	—	26,376
2019-11-20	CELGENE CORP /DE/Stock Option (right to buy)D Disposition to Issuer	PRES., GLOBAL HEM. AND ONC.	DDisposition to Issuer	−5,626 sh	—	—	0
2019-11-20	CELGENE CORP /DE/Stock Option (right to buy)D Disposition to Issuer	PRES., GLOBAL HEM. AND ONC.	DDisposition to Issuer	−5,624 sh	—	—	0
2019-11-20	CELGENE CORP /DE/Stock Option (right to buy)D Disposition to Issuer	PRES., GLOBAL HEM. AND ONC.	DDisposition to Issuer	−1,750 sh	—	—	0
2019-11-20	CELGENE CORP /DE/Stock Option (right to buy)D Disposition to Issuer	PRES., GLOBAL HEM. AND ONC.	DDisposition to Issuer	−6,563 sh	—	—	0
2019-11-20	CELGENE CORP /DE/D Disposition to Issuer	PRES., GLOBAL HEM. AND ONC.	DDisposition to Issuer	−1,966 sh	—	—	0
2019-11-20	CELGENE CORP /DE/D Disposition to Issuer	PRES., GLOBAL HEM. AND ONC.	DDisposition to Issuer	−40.7K sh	—	—	0

Recent filings

Accepted (ET)
Jun 234
AHMED NADIM0001193125-26-279690
SEC(opens sec.gov)
Feb 254
AHMED NADIM0001193125-26-072001
SEC(opens sec.gov)
Feb 234
AHMED NADIM0001193125-26-064254
SEC(opens sec.gov)
Feb 194
AHMED NADIM0001193125-26-059639
SEC(opens sec.gov)
Dec 294
AHMED NADIM0001193125-25-335482
SEC(opens sec.gov)
Jul 164
AHMED NADIM0000950170-25-096357
SEC(opens sec.gov)
Feb 274
AHMED NADIM0000950170-25-029199
SEC(opens sec.gov)
Feb 214
AHMED NADIM0000950170-25-025029
SEC(opens sec.gov)
Dec 274
AHMED NADIM0000950170-24-140856
SEC(opens sec.gov)
Feb 234
AHMED NADIM0000950170-24-019462
SEC(opens sec.gov)
Dec 274
AHMED NADIM0000950170-23-073405
SEC(opens sec.gov)
Jun 294
AHMED NADIM0000950170-23-030805
SEC(opens sec.gov)
May 244
AHMED NADIM0000950170-23-023939
SEC(opens sec.gov)
Apr 264
AHMED NADIM0000950170-23-014838
SEC(opens sec.gov)
Mar 274
AHMED NADIM0000899243-23-009714
SEC(opens sec.gov)
Feb 234
AHMED NADIM0000899243-23-006004
SEC(opens sec.gov)
Jul 54
AHMED NADIM0000899243-22-025077
SEC(opens sec.gov)

Companies

Address

C/O DISC MEDICINE, INC. 321 ARSENAL STREET, SUITE 101

WATERTOWN, MA, 02472